LCRF and Bayer Pharmaceuticals Collaborate on Research Grant
In an effort to enhance therapeutic strategies for lung cancers driven by HER2 alterations, the Lung Cancer Research Foundation (LCRF) has announced a significant funding opportunity in collaboration with Bayer Pharmaceuticals. This initiative aims to address the urgent need for research focusing on lung cancers harboring HER2 mutations.
Details of the Research Award
The LCRF|Bayer Research Award, amounting to $500,000 over two years, encourages innovative research aimed at novel therapeutic strategies specifically targeting lung cancers with HER2 mutations. This award underscores the necessity for deeper exploration into the mechanisms behind tumor responses and resistance to current treatments.
The Importance of Innovative Research
Current treatments for HER2-driven lung cancers have limited success, often due to existing therapies not being curative. As a result, the foundation's initiative is particularly focused on innovative research efforts. By encouraging researchers to delve into HER2 alterations as oncogenic drivers, the grant seeks to produce groundbreaking advancements in treatment.
Research Goals and Requirements
The funded projects will tackle critical questions regarding therapy and the disease spectrum, with a goal of enhancing patient survival rates. Importantly, proposals are encouraged to include clinical trials to bridge the gap between research findings and practical applications in patient care. Projects must also ensure that a patient or patient advocate is involved in the research team and plays an active role in the project design.
Quotes from Key Figures
Dr. Antoinette Wozniak, Chief Scientific Officer at LCRF, emphasized the significance of expanding treatment options for patients affected by HER2 mutations and alterations, stating, "Through this award, we hope to support research that drives near-term breakthroughs with tangible benefits for patients."
Submission Process for Proposals
The submission process for this award involves a two-step review system. Researchers must submit Letters of Intent by a specified deadline, after which selected proposals will be invited to submit full applications. Each application will undergo a stringent review by LCRF's Scientific Advisory Board to ensure high-quality research investments.
Expectations and Timeline
The specific deadline for submitting Letters of Intent is a few months from now, ensuring researchers ample time to prepare their proposals. Detailed eligibility criteria, requirements, and deadlines for the Request for Proposals can be accessed directly through LCRF’s official website.
About the Lung Cancer Research Foundation
The Lung Cancer Research Foundation is a leading nonprofit organization dedicated to funding groundbreaking research aimed at improving outcomes for lung cancer patients. With a commitment to extend survival and enhance quality of life, LCRF has funded over 420 research grants amounting to nearly $48 million, representing the highest funding by a nonprofit in this field.
Contact Information
For further inquiries regarding this funding opportunity, please reach out to the Lung Cancer Research Foundation. Sheila Sullivan, the Senior Director of Marketing & Communications, is available for questions.
Frequently Asked Questions
What is the purpose of the LCRF|Bayer Research Award?
The award aims to support innovative therapeutic strategies for lung cancers driven by HER2 mutations.
How much funding is available through the LCRF program?
A total of $500,000 is allocated for the two-year research grant.
Who can apply for this research funding?
Researchers with proposals focused on HER2-driven lung cancers are eligible to apply.
When are proposals due?
Letters of Intent must be submitted by a designated deadline, which will be communicated on the LCRF website.
What is significant about HER2 mutations in lung cancer?
HER2 mutations pose challenges for existing therapies, making innovative research essential for improving patient outcomes.
